TP53 is known for its role in BE malignant progression (Paulson et al., 2022; Pinto et al., 2022), improved prediction of BE neoplastic progression (Redston et al., 2022), increased risk of dysplasia when abnormally expressed, and improved intra-observer agreement in dysplastic diagnosis (Januszewicz et al., 2022). Here, TP53 is linked to Barrett esophagus.